Ongoing research aims to improve the accuracy of ERBB2 testing and to develop new therapeutic strategies. Advances in next-generation sequencing (NGS) and liquid biopsy techniques hold promise for more precise detection and monitoring of ERBB2 status. Furthermore, understanding the mechanisms behind resistance to ERBB2-targeted therapies could lead to the development of combination therapies that enhance treatment efficacy.
